Stocks · News reference

Benitec Biopharma Says FDA Requested More Data On Single-Arm Pivotal Study Of BB-301 In Oculopharyngeal Muscular Dystrophy; Expects Final Design In Q1 2027

Oct 5, 2026, 12:06 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 5, 2026, 5:24 PMBenzinga Newsdesk
Benitec Biopharma shares are trading higher after the company announced that BB-301 pivotal trial remains on track to begin in mid-2027 and the final pivotal study design is expected to be confirmed in Q1 2027.
BNTC
SEC EDGAROct 5, 2026, 12:08 PMSEC EDGAR
8-K filing — Benitec Biopharma Inc. (BNTC)
Filed: 2026-10-05 AccNo: 0001193125-26-413177 Size: 192 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
BNTC
BenzingaSep 15, 2026, 1:38 PMBenzinga Newsdesk
Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17
Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $16 to $17.
BNTC